Johnson & Johnson (NYSE:JNJ) Receives $199.05 Consensus Price Target from Analysts

11 Nov 2025, 06:58 by Mitch Edgeman · The Markets Daily

Johnson & Johnson (NYSE:JNJ – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-six research firms that are currently covering the firm, MarketBeat.com reports. Nine equities research analysts have rated the stock with a hold recommendation, fourteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $199.05.

Several equities analysts have recently issued reports on the company. HSBC boosted their target price on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday, October 16th. Daiwa Capital Markets raised shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research note on Monday, October 20th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the stock an “overweight” rating in a report on Friday, October 3rd. Finally, Loop Capital set a $190.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 22nd.

View Our Latest Analysis on JNJ

Johnson & Johnson Trading Up 0.9%

JNJ opened at $188.29 on Friday. The firm has a 50 day simple moving average of $184.47 and a 200 day simple moving average of $169.03. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a market cap of $453.65 billion, a price-to-earnings ratio of 18.17, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The company had revenue of $24.02 billion during the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s payout ratio is presently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Hedge Funds Weigh In On Johnson & Johnson

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RWA Wealth Partners LLC raised its position in Johnson & Johnson by 5.5% in the 3rd quarter. RWA Wealth Partners LLC now owns 378,652 shares of the company’s stock valued at $70,210,000 after buying an additional 19,714 shares during the last quarter. Cary Street Partners Financial LLC increased its stake in Johnson & Johnson by 0.8% in the 3rd quarter. Cary Street Partners Financial LLC now owns 132,069 shares of the company’s stock valued at $24,488,000 after buying an additional 1,103 shares during the last quarter. Vawter Financial Ltd. bought a new stake in Johnson & Johnson during the 3rd quarter worth about $570,000. JFS Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 3.2% during the 3rd quarter. JFS Wealth Advisors LLC now owns 31,271 shares of the company’s stock worth $5,798,000 after buying an additional 984 shares during the last quarter. Finally, Waddell & Associates LLC grew its holdings in shares of Johnson & Johnson by 22.6% in the 3rd quarter. Waddell & Associates LLC now owns 10,065 shares of the company’s stock valued at $1,866,000 after acquiring an additional 1,856 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

About Johnson & Johnson

(Get Free Report)